Key Highlights

  • Q3 2026 Revenue reached $110.0 million, 52% below the $231.1 million of a year before.
  • Net red ink reached $32.7 million, or $0.64 a diluted share, versus $51.2 million of profit a year before.
  • Adjusted EBITDA swung to a $4.6 million loss from a profit of $92.6 million.
  • Full-year revenue expectations for 2026 were lowered to a band of $600 million to $645 million, previously $645 million to $675 million.
  • Gross Debt sits at $514 million, and net Leverage is 2.4 times trailing 12-month adjusted EBITDA, per management.

Naloxone and Smallpox Sales Shrink as Quarterly Revenue Drops by Over Half

Emergent BioSolutions (NYSE:EBS) published its quarterly numbers on Nov 2, 2026, for the period to Sep 30, 2026. Sales totaled $110.0 million, a 52% fall in line with guidance. Red ink totaled $32.7 million ($0.64 a diluted share), whereas the prior-year period had profit of $51.2 million, or $0.91 a share.

The portfolio covers biological threat countermeasures and the NARCAN and KLOXXADO nasal naloxone sprays. Naloxone sales declined 42% to $43.5 million, with Canada providing a partial cushion against softer over-the-counter NARCAN prices and reduced U.S. public interest volume. Smallpox countermeasures fell 68% to $26.7 million due to order timing.

Anthrax sales jumped to $25.1 million, compared with $1.4 million, reflecting when the U.S. government bought. Other products dropped 87% to $7.6 million.

Margin Compression to 14% and an Adjusted EBITDA Shortfall of $4.6 Million

Reported gross Margin fell to 14% from 54%, and the adjusted version to 28% from 62%. Adjusted EBITDA swung to a $4.6 million loss, a negative 4% margin, against an earlier $92.6 million at a 40% margin. The adjusted Bottom Line came to a $18.7 million deficit, or $0.36 a share.

SG&A climbed 20%, arriving at $46.5 million, owing to August 2026 restructuring severance, relative to a prior-year quarter that held a one-time litigation insurance reimbursement. R&D decreased 30%, ending at $9.4 million. About $40 million of annualized savings is expected from the fourth quarter.

Nine-month sales were $500.4 million, against $594.2 million earlier. The bottom line showed a $206.1 million loss, which contained a non-cash write-down of $191.3 million taken in the second quarter.

Full-Year Outlook Trimmed on Sales While the Adjusted Gross Margin Target Expands

Full-year 2026 revenue is now projected at $600 million to $645 million, versus an earlier band of $645 million to $675 million established Aug 5, 2026. Adjusted EBITDA expectations now sit between $110 million and $140 million, previously $130 million and $150 million.

Countermeasure revenue is expected to decline, as certain shipments abroad and to federal buyers could slip beyond the fourth quarter, and commercial sales look set for the low end of a 20% to 25% drop. Adjusted gross margin guidance moved into a 45% to 47% band from 42% to 44%, citing Manufacturing gains, mix and steadier NARCAN pricing.

Nine-Month Cash Generation Improves Alongside Note Repurchases and a CFO Departure

Nine-month Operating Cash Flow reached $122.4 million, versus $92.9 million. Liquidity was $226 million, including $175.7 million of cash. Buying back $75 million of unsecured notes took $68 million, and gross debt now stands at $514 million with net debt at $339 million. Repurchased stock totaled 2.0 million shares, a $18.1 million outlay, leaving $37.3 million under authorization.

The finance chief will step down on Dec 31, 2026. Where full-year sales land in the range depends on when pending government and foreign deliveries arrive in late 2026 and early 2027, management said.